Zevalin
information and resources from the National Cancer Institute
Zevalin
(Other name for: yttrium Y 90 ibritumomab tiuxetan)
Ibritumomab Tiuxetan
Accel. Approv. (clinical benefit not established) treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab refractory follicular non-Hodgkin’s lymphoma.
IDEC Pharmaceuticals Corp Feb 19 2002
|
|
|
|
news articles
An infusion of new hope Mar 31, 2006
Globe and Mail, Yesterday, the 54-year-old underwent an infusion of Zevalin at Royal Victoria Hospital in Montreal, putting an end to a months-long battle of trying to find a ...
Ailing woman is offered care Mar 17, 2006
Globe and Mail, ...a day after The Globe and Mail published a story on how the 54-year-old was relegated to her bed most days, while a costly drug called Zevalin, provided free ...
Woman's last hope tied up in red tape Mar 16, 2006
Globe and Mail, Instead of receiving the 10-minute infusion of Zevalin that could beat back a stubborn cancer, the 54-year-old spends much of her day in bed, wearing a ...
Snowe Jobs Mar 16, 2006
American Spectator Medicare. She is waiting to use a drug called Zevalin, which works in 80 percent of people with advanced forms of large cell lymphoma. ...
VGX and Dowpharma sign cancer compound agreement Mar 10, 2006
In-PharmaTechnologist.com, Currently, Schering AG is the leader in the haematological oncology market, with products such as Zevalin, for which Schering has received the European ...
TRACON Pharmaceuticals Assembles Industry-Leading Management Team ... Mar 15, 2006
Yahoo! News (press release) ...of oncology products in development, including the regulatory filings that supported the approval of Rituxan® (rituximab) and Zevalin® (ibritumomab tiuxetan ...
Zevalin Used in Abbreviated Chemotherapy Regimen Shows Efficacy ... Dec 16, 2005
DG News ATLANTA, GA -- December 16, 2005 -- Three cycles of CHOP-rituximab (CHOP-R) followed by ibritumomab tiuxetan (Zevalin) and rituximab induces a high rate of ...
New Data Demonstrate ZEVALIN(R) Radioimmunotherapy May Play ... Dec 13, 2005
Genetic Engineering News, Society of Hematology (ASH) in Atlanta, December 10-13, demonstrate that patients may benefit from earlier and consolidated use of ZEVALIN(R) (Ibritumomab ...
Chemotherapy Consolidation with Zevalin(R) (90Y-Ibritumomab ... Dec 12, 2005
PR Newswire UK (press release), According to recent trial findings, the consolidation of standard chemotherapy with Zevalin(R) (90Y-Ibritumomab tiuxetan), was well-tolerated, safe and ...
Biogen Idec releases Zevalin data Dec 13, 2005
San Diego Daily Transcript (subscription), Society of Hematology in Atlanta demonstrates that patients may benefit from earlier and consolidated use of the company's Zevalin radioimmunotherapy in ...
Association of Severe Mucocutaneous Reactions with the Zevalin ... Dec 12, 2005
DG News Johnson syndrome and toxic epidermal necrolysis, have been reported postmarketing in association with the administration of the Zevalin therapeutic regimen. ...
Adding Radioimmunotherapy To Chemotherapy Reduces Relapse Risk In ... Dec 17, 2005
Medical News Today (press release), Zevalin (yttrium-90-ibritumomab tiuexetan) is a monoclonal antibody bound with a cancer-killing radioisotope that specifically targets lymphatic tumors. ...
Chemotherapy Consolidation with Zevalin(R) (90Y-Ibritumomab ... Dec 12, 2005
Biotech Intelligence (press release), ATLANTA, December 12/PRNewswire/ -- According to recent trial findings, the consolidation of standard chemotherapy with Zevalin(R) (90Y-Ibritumomab tiuxetan ...
Pharmacyclics Announces Presentation and Publication of ... Dec 12, 2005
PR Newswire (press release), ...results of a Phase 1 clinical trial, which suggest that Xcytrin(R) (motexafin gadolinium) Injection, when given in combination with Zevalin(R) (Ibritumomab ...
Pharmacyclics Announces Presentation and Publication of ... Dec 12, 2005
Yahoo! News (press release) ...of a Phase 1 clinical trial, which suggest that Xcytrin® (motexafin gadolinium) Injection, when given in combination with Zevalin® (Ibritumomab Tiuxetan), is ...
Pharmacyclics' Stock Crushed After Failed Phase III Of Xcytrin Dec 19, 2005
BioWorld Online (subscription), ...released data from earlier-stage studies of Xcytrin: Phase I results showed Xcytrin injection, when given in combination with Zevalin (ibritumomab tiuxetan ...
Pharmacyclics Announces Presentation and Published Abstracts on ... Dec 6, 2005
PharmaLive.com (press release), Title: Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin(R); 90Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete ...
New Treatment Regimen May Improve Mantle Cell Lymphoma: Presented ... Dec 14, 2005
DG News ATLANTA, GA -- December 14, 2005 -- A new study shows that chemotherapy paired with Y-ibritumomab tiuxetan (Zevalin) might improve outcomes for patients with ...
Pharmacyclics Announces Presentation and Published Abstracts on ... Dec 6, 2005
PR Newswire (press release), ...follows: Sunday, December 11, 2005 Poster Session 654-II Title: Combination of Motexafin Gadolinium (MGd) with 90Y Ibritumomab Tiuxetan (Zevalin(R); 90Yttrium ...
MDS Reports Fourth Quarter and Fiscal 2005 Financial Results Dec 14, 2005
Canada NewsWire (press release), In September, we were chosen by Berlex Canada to supply Yttrium-90 Chloride Sterile Solution (Y-90) for use with Berlex's ZEVALIN(R) radioimmunotherapy ...
(PRN) - Option Recognized as a Red Herring Small Cap 100 ... [+] Dec 12, 2005
Bolsamania.com, ...[+]. (PRN) - Chemotherapy Consolidation with Zevalin(R) (90Y-Ibritumomab tiuxetan) May Provide Therapeutic Benefit for Mantle Cell Lymphoma Patients ... [+. ...
|
|
